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Abstract
Introduction: An international cohort study of 73 anti-Ku-positive patients with different connective tissue diseases
was conducted to differentiate the anti-Ku-positive populations of patients based on their autoantibody profile and
clinical signs/symptoms and to establish possible correlations between antibodies against Ku p70 and Ku p80 with
autoimmune diseases.
Methods: Sera of anti-Ku-positive patients were collected from six European centers and were all secondarily
tested (in the reference center); 73 were confirmed as positive. Anti-Ku antibodies were detected with counter-
immunoelectrophoresis (CIE), line immunoassay (LIA), and immunoblot analyses. All clinical and laboratory data
were follow-up cumulative data, except for anti-Ku antibodies. Statistical analyses were performed by using
R (V 2.12.1). The Fisher Exact test was used to evaluate the association between anti-Ku antibodies and diagnosis,
gender, clinical signs, and other observed antibodies. The P values were adjusted for multiple testing. Separation of
disease populations based on the presence of antibodies and clinical signs was investigated by principal-
components analysis, which was performed by using thr// R’s prcomp function with standard parameters.
Results: A 16% higher prevalence of anti-Ku p70 was found over anti-Ku p80 antibodies. In 41 (57%) patients, a
combination of both was detected. Five (7%) patients, who were CIE and/or LIA anti-Ku positive, were negative for
both subsets, as detected with the immunoblot; 31% of the patients had undifferentiated connective tissue disease
(UCTD); 29% had systemic sclerosis (SSc); 18% had systemic lupus erythematosus (SLE); 11% had rheumatoid
arthritis; 7% had polymyositis; and 3% had Sjögren syndrome.
Conclusions: A significant positive association was found between female patients with anti-Ku p70 and joint/
bone features, and a significant negative association was found between female patients with anti-Ku p80 only and
joint/bone features (P = 0.05, respectively). By using the first and the third components of the principal-component
analysis (PCA) with 29 parameters evaluated, we observed that the anti-Ku-positive population of UCTD patients
had overlapping parameters, especially with SLE, as opposed to SSc, which could be helpful in delineating UCTD
patients.
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Introduction
The Ku complex is a heterodimer made of p70 and p80
subunits that play major roles in DNA repair, transcrip-
tional regulation, and replication and have also been
involved in telomere maintenance, V(D)J recombination,
and development of the brain. Ku is ubiquitously found in
the nucleus; however, it has also been localized in the
cytoplasm, as well as on cellular surfaces [1-3]. In humans,
Ku p70 and Ku p80 genes are localized on different chro-
mosomes (22q13 and 2q33, respectively). Their proteins
share sequence homologies, as well as display marked
structural homologies. Ku p70 and Ku p80 are generally
believed to form and function as a heterodimer, but each
also has its own unique activities. Whereas p70 resembles
a transcriptional activator, and its DNA-binding domain
has been localized to its C-terminus, p80 does not seem to
bind DNA and may be involved in interactions with other
proteins [4]. The differences also extend to knockout mice
models. Ku70-knockout mice showed deficiencies in sub-
groups of mature T lymphocytes and a significant inci-
dence of thymic lymphoma, whereas Ku p80-knockout
mice had arrested T-and B-cell development at early
stages and caused growth retardation [5,6].
Although antibodies against Ku antigen (anti-Ku) were
originally described in patients with scleroderma-poly-
myositis overlap syndrome, reports showed that anti-Ku
antibodies are found also in many diseases, in particular,
in patients with systemic lupus erythematosus (SLE),
systemic sclerosis (SSc), and undifferentiated connective
tissue disease (UCTD) [7]. The prevalence of anti-Ku
antibodies has recently been evaluated in a European
EUSTAR-initiated multicenter case-controlled study with
625 SSc patients in whom a clinically distinct subset
resulted in 14 anti-Ku-positive patients (2.2%) [8]. The
presence of anti-Ku antibodies in the study of Rozman
et al. [8] was reported to be associated with synovitis,
joint contractures, and clinical features of myositis, and
negatively associated with vascular manifestation of dis-
ease. Cavazzana et al. [7] retrospectively analyzed the
prevalence and clinical signs of anti-Ku antibodies in
patients affected by different autoimmune diseases. Most
of anti-Ku-positive patients were found to be affected by
UCTD and overlap syndromes, including polymyositis,
SSc, and SLE. Interstitial lung disease, myositis, articular
symptoms, Raynaud phenomenon, and sicca syndrome
represented the main clinical features detected in this
cohort. Both recent studies give a broad overview of anti-
Ku antibodies and clinical, serologic, and diagnostic
correlations.
In 1989, Reeves et al. [9] reported on levels of antibo-
dies against Ku p70 and Ku p80 longitudinally over a per-
iod of 70 months in sera of patients with SLE (n = 2),
mixed connective tissue disease (n = 1), and Sjögren
syndrome (n = 1). Their study suggested that anti-Ku
p70/anti-Ku p80 antibodies are generated by a selective
antigen-driven mechanism; however, polyclonal activa-
tion also frequently accompanied autoantibody produc-
tion. Human Ku autoantibodies are thought to react with
at least eight different epitopes of the human complex
[10]. SLE sera reacted on immunoblots with at least three
epitopes of p70 (aa 560-609, 506-535, and 115-467), and
three epitopes of p80 (aa 682-732, 558-681, and 1-374);
one strong antigenic region (immunodominant epitope
of p70) was revealed near the C-termini of p70 (confor-
mational or discontinuous epitope) and p80 [11].
Yaneva and Arnett [12] examined anti-Ku p70/anti-Ku
p80 antibodies with quantitative immunoblotting and
found that all positive sera (from mixed ethnic patients
with SLE (n = 13), SSc (n = 9), myositis (n = 2), and Sjög-
ren syndrome (n = 2)) had antibodies against Ku p80, and
only one serum (from a dermatomyositis patient) did not
react with Ku p70. Only anti-Sm antibodies appeared to
be associated with anti-Ku antibodies.
The aim of our study was to examine whether disease
populations, with special emphasis on UCTD, could be
depicted based on their associated clinical and laboratory
data by using principal-component analysis (PCA). Further,
we aimed to investigate the association of anti-p70 and/or
anti-p80 antibodies with the presence of clinical signs,
autoimmune diseases, and their respective autoantibodies.
Therefore, we evaluated the largest European cohort study
to date with 73 anti-Ku-positive patients.
Materials and methods
Subjects
Sera of anti-Ku-positive patients were collected from six
European centers (Ljubljana, Brescia, Pécs, Prague, Nis,
and Vienna) and were all secondarily tested; 73 were con-
firmed as positive in Ljubljana. Among them were 61
female and 12 male subjects. Their mean age was 57.8
years, ranging from 16 to 86 years. Anti-Ku positivity was
determined with counter-immunoelectrophoresis (CIE)/
line immunoassay (LIA) in the Immunological Labora-
tory of the Department of Rheumatology, University
Medical Center, Ljubljana. Among these, only one patient
was LIA but not CIE positive. The diagnoses of SSc, SLE,
rheumatoid arthritis, polymyositis, and Sjögren syndrome
were defined in the participating centers according to
well-established criteria [13-17]. The criteria for UCTD
were used, as suggested by Distler et al. [18] because this
disease has no uniformly accepted diagnostic criteria.
The overlaps were gathered under the diagnosis, which
represented the leading clinical symptoms and signs of
the disease.
Because of the large amount of clinical and laboratory
data, besides some single clinical and laboratory
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features, a more simplified version of presenting the
compilation of data was used.
• SLE skin” is defined by the presence of one or
more of the following: malar rash, discoid rash,
photosensitivity
• Joint and bone” is defined by the presence of one
or more of the following: Joint features were evalu-
ated clinically (synovitis and joint contractions) and
by radiographic examination (erosive arthritis, acro-
osteolysis)
• Muscle” is defined by the presence of one or more
of the following: weakness or atrophy of muscles,
serum CK elevation, EMG, and muscle biopsy in
line with the appropriate criteria for inflammatory
myopathy
• Neurology” is defined by the presence of one or
more of the following: seizures, psychosis, or periph-
eral neuropathy
• Gastrointestinal” is defined by the presence of one
or more of the following: dysphagia, gastroesopha-
geal reflux, or early satiety
• Pulmonary” is defined by the presence of one or
more of the following: dyspnea, NYHA I/II, fibrosis
(plain radiograph), restrictive defect, or pleuritis
• Heart” is defined by the presence of one or more
of the following: palpitations, conduction blocks, or
abnormal diastolic function
• Renal” is defined by the presence of one or more
of the following: proteinuria (more than 0.5 g/day),
renal insufficiency, or renal crisis
• Antiphospholipid antibodies” are defined by the
presence of one or more of the following: anticardio-
lipin antibodies, or anti-b2-glycoprotein antibodies,
lupus anticoagulant, detected at least on two occa-
sions, as defined by APS criteria [19]
• Cytopenia” means a low number of leukocytes
and/or erythrocytes and/or thrombocytes
All clinical and laboratory data are follow-up cumula-
tive data, except for anti-Ku antibodies, as determined
with CIE/LIA and anti-p70/anti-p80 immunoblot detec-
tion. Informed consent was obtained, and the study was
approved by the Ethics Committee of the Slovenian
Ministry of Health.
Methods
Stored sera were sent on dry ice to the reference center
(Department of Rheumatology, Ljubljana), where they
were tested. Antibodies against soluble nuclear antigens
(anti-ENA): Ro/SS-A, La/SS-B, Sm, U1RNP, PCNA, SL,
Scl-70, PM/Scl, Jo-1, and Ku were screened with CIE, as
described [20], which show conformational epitopes and
are not able to discriminate between anti-Ku p70 and/or
anti-Ku p80.
Sera from the aforementioned centers were addition-
ally tested in the same reference center for antinuclear
antibodies (ANAs) with indirect immunofluorescence on
HEp-2 cell-line substrate (Immunoconcepts, Sacra-
mento, CA, USA) and with LIA for autoantibodies pre-
sent in myositis, which detects, besides anti-Ku, also
antibodies against Jo-1, Mi-2, PM/Scl, and U1-snRNP
(Imtec-Myositis-LIA; Imtec, Immunodiagnostika, Berlin,
Germany). The Ku antigen on Imtec-Myositis-LIA is a
human recombinant Ku p70/p80, which also does not
distinguish between the two subunits. Hep-2 patterns
were detected with indirect immunofluorescence, rheu-
matoid factor, with latex fixation test and Waaler Rose
reaction, anti-cyclic citrullinated protein antibodies with
enzyme-linked immunosorbent assay (ELISA; Immunos-
can CCPlus, Euro-Diagnostica AB, Malmö, Sweden),
aPL with an in-house ELISA (for anti-aCL IgG and IgM
isotypes and for anti-b2-GPI, IgG, IgM, and IgA have
been measured) and anti-dsDNA antibodies with an in-
house FARR-RIA assay.
To detect anti-p70 and anti-p80 antibodies, immuno-
blotting was used. Nuclear extracts were prepared from
THP-1 (human acute monocytic leukemia cell line). Cen-
trifuged THP-1s were washed with PBS, and protease
inhibitors (Halt Protease Inhibitor Cocktail Kit; Pierce,
Rockford, IL, USA) were added. Extraction was done
according to instructions (NE-PER Nuclear and Cyto-
plasmic Extraction Reagents; Pierce), and protein con-
centration in nuclear extract was measured with the
Bio-Rad Protein Assay (Bio Rad, Munich, Germany). The
immunoblot method included an initial immunoprecipi-
tation step, which was performed with Protein A/G
PLUS-Agarose Immunoprecipitation Reagent; Santa
Cruz, Santa Cruz, CA, USA): 500 μg of proteins from the
nuclear extract was mixed with 2 μg mouse monoclonal
antibody Ku-3 (clone 162) (NeoMarkers, Fremont, CA)
and incubated 2 hours at 4°C. Then 20 μl of resuspended
A/G Agarose was added, and the mixture was incubated
another 2 hours at 4°C. Washing of pellet was done with
PBS for 4 times, each time followed by centrifugation.
After the final wash, pellets were resuspended in PBS and
electrophoresis SDS-sample buffer and boiled for 3 min-
utes for protein elution. Sample volume corresponding to
50 μg of primary nuclear extract/cm of gel length was
analyzed on 10% SDS-polyacrylamide gels in Tris/glycine
buffer in BioRad Mini Protean apparatus and transferred
to nitrocellulose (BA 85; Schleicher & Schuell, Munich,
Germany) at 100 V, 250 mA for 45 minutes. The dry
membrane was blocked with TBS/0.05% Tween buffer
with 5% milk. Patient sera were diluted 1:50 and incu-
bated 2 hours, followed by washing and 40 minutes of
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goat anti-human IgG-HRP (1:1,000) (BioRad) incubation.
Detection was done with luminol (Western Blotting
Luminol Reagent, Santa Cruz, CA, USA) in G:box (Syn-
gene, Cambridge, UK) with chemiluminescence. As posi-
tive controls, monoclonal goat antibodies (Ku-86 (C-20),
Santa Cruz; Ku-70 (C-19), Santa Cruz, diluted 1:500) and
donkey anti-goat IgG-HRP conjugate (diluted 1:1,000,
Santa Cruz) were used. All samples were tested also for
colorimetric determination, and the secondary antibodies
used were rabbit anti-human alkaline phosphatase (Bio
Rad) followed by the substrate NBT/BCIP (Pierce).
Statistical analyses
Statistical analyses were performed by using R (V 2.12.1)
[21]. The Fisher Exact test was used to evaluate the
association between anti-Ku antibodies and diagnosis,
gender, clinical signs, and other observed antibodies.
The P values were adjusted for multiple testing by using
the approach of Benjamini and Hochberg [22]. An
adjusted P value below or equal to 0.05 was considered
statistically significant. Separation of disease populations
based on the presence of antibodies and clinical signs
were investigated with PCA. PCA was performed by
using the R prcomp function with standard parameters.
PCA allows the identification of latent variables (princi-
pal components) in the data based on observed variables
(in our case, 29 parameters, the presence of those auto-
antibodies and clinical signs that show five or more
observations).
Results
Anti-Ku p70/80 prevalence
Within our anti-Ku-positive population (n = 73), 60
(83%) anti-Ku p70-positive patients were found, whereas
48 (67%) patients were anti-Ku p80 positive. This repre-
sents a 16% higher prevalence of anti-Ku p70 over anti-
Ku p80. For one UCTD patient, the immunoblot p70/
p80 differentiation was not able to be performed. Nine-
teen (26%) patients had only anti-Ku p70, whereas seven
(10%) patients had only anti-Ku p80 antibodies detected
(Table 1). In 41 (57%) patients, a combination of both
anti-p70/anti-p80 antibodies was seen. Only five (7%)
patients who were CIE anti-Ku positive were negative
for both subsets of antibodies in the immunoblot (Table
1). Twenty anti-Ku-negative controls (blood donors)
were tested only in the immunoblots and did not show
any reactivity (data not shown).
Anti-Ku p70/80 association with clinical signs, symptoms,
and diagnosis
We next analyzed associations with clinical symptoms
and presentations. An overview of associations between
anti-Ku-positive patients, as determined by CIE/LIA,
with clinical signs and symptoms is given in Figure 1.
When looking specifically at anti-Ku p70 and/or anti-Ku
p80, a significantly positive association between anti-Ku
p70 antibodies was exclusively found with joint/bone fea-
tures (synovitis, erosive arthritis, joint contractures, and
acro-osteolysis) (P = 0.05), whereas a significant negative
correlation was found between anti-Ku p80 antibodies
only and joint/bone features, even after adjustment of the
P value for multiple testing. Both findings were in female
patients. No significant associations were found between
the presence of anti-Ku p70 and/or anti-Ku p80 antibo-
dies and any of the diagnoses, even when sex or age-
related associations were considered.
Anti-Ku p70/80 association with other autoantibodies
A summary of the percentage of anti-Ku-positive patients,
as determined by CIE/LIA to all autoantibodies measured
in this study, is shown in Figure 2. A single anti-Ku posi-
tive (positive for both anti-Ku p70 and anti-Ku p80 antibo-
dies) anti-centromere antibodies (ACA)-positive case was
found, and this patient was clinically diagnosed as having
SLE/Sjögren syndrome. All but one anti-Ku-positive
patients were ANA positive, showing mostly a speckled or
a speckled plus nucleolar immunofluorescence pattern in
all groups.
No significant associations were found between the pre-
sence of anti-Ku p70 and/or anti-Ku p80 antibodies and
any autoantibodies, when sex- or age-related associations
were considered. However, before adjustment of the P
value, a significant positive association was found between
antiphospholipid antibodies and anti-Ku p80 antibodies
only, in both the overall and female populations.
Patient stratification based on presence of clinical signs
and antibodies
To investigate whether it is possible to stratify the patients
diagnosed with SLE, UCTD, and SSc based on their auto-
antibody status and clinical signs/symptoms, we used PCA
(Figure 3). The principal components (PCs) are ordered
according to the amount of variance in the data they
explain, with PC1 being the most informative.
By using PC1 and PC3 for the PCA, we observed that
the anti-Ku-positive SLE and SSc populations had little
overlap, whereas the anti-Ku-positive UCTD patients in
our cohort had a greater overlap with anti-Ku-positive
SLE patients than with anti-Ku-positive SSc patients.
Discussion
A significant association was recently demonstrated
between the presence of anti-Ku antibodies and musculos-
keletal features in SSc [8]. The current study focuses on
the differences between the clinical presentation of anti-
Ku p70- and anti-Ku p80-positive patients, regardless of
their diagnoses. The study included six European centers,
all known for their expertise in the field of systemic
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autoimmune diseases. With a total of 73 patients, this
cohort is the largest to date and showed an overall 16%
higher prevalence of antibodies detected against the Ku
p70 subunit as compared with Ku p80, which is a novel
finding. These data differ from those of a study by Wang
et al. [23], in which they showed a 28% higher prevalence
of autoantibodies against p80 on a total of 58 systemic
autoimmune patients; however, this population was exam-
ined in the United States and presumably differs from our
European cohort. Additionally, the anti-Ku antibodies
were detected with ELISA or immunoprecipitation by
using K562 cell Ku antigen, and the clinical diagnoses and
disease definitions differed from those used in our study,
which could have also influenced the results. The same
report also indicates the presence of stabilizing autoanti-
bodies (in terms of stabilizing intermolecular contacts
between the p70 and p80 Ku subunits) against both
recombinant antigens. In the current study, UCTD and
SSc patients were the most prevalent in the anti-Ku-posi-
tive group, whereas in the Wang et al. [21] study, SLE and
mixed connective tissue disease overlap patients were
highest in number.
Epitope mapping has identified at least eight autoepi-
topes on the Ku antigen, located on p70, p80, or both
Table 1 Prevalence of anti-Ku p70/p80 in patient groups as detected with immunoblot analysis
Diagnosis Number of patients Ku p70 Ku p80 Ku p70 only Ku p80 only Ku p70 and Ku p80 Ku pXX
None
PM/DM 6 4 (67%) 3 (50%) 2 (33%) 1 (17%) 2 (33%) 1 (17%)
RA 8 7 (88%) 6 (75%) 2 (25%) 1 (13%) 5 (63%) 0 (0)
SLE 13 10 (77%) 11 (84%) 1 (8%) 2 (15%) 9 (69%) 1 (8%)
SS 2 2 (100%) 2 (100%) 0 (0) 0 (0) 2 (100%) 0 (0)
SSc 21 17 (81%) 11(52%) 8 (38%) 2 (10%) 9 (43%) 2 (10%)
UCTD 22 20 (91%) 15 (68%) 6 (27%) 1 (5%) 14 (64%) 1 (5%)
Total 72 60 (83%) 48 (67%) 19 (26%) 7 (10%) 41 (57%) 5 (7%)
Numbers of patients in each group are indicated, followed by the percentage. Ku pXX.none, neither anti-Ku p70 nor anti-Ku p80 present; PM/DM, polymyositis/
dermatomyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; SSc, systemic sclerosis; UCTD, undifferentiated connective
tissue disease.
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subunits, suggesting strongly that an antigenic confor-
mational epitope exists on the C-terminus of p70 and
p80 [11]. In our case, five of the patients (7%) who were
anti-Ku positive by CIE/LIA were negative for both sub-
sets of antibodies in the immunoblot assay and could be
implied to recognize a conformational epitope.
No significant association was found between anti-Ku
p70 and/or anti-Ku p80 and any of the diagnoses, even
when looking for sex- and/or age-related associations.
However, a significant positive correlation (P = 0.05)
was found between anti-Ku p70 and joint/bone features,
and a significantly negative correlation was shown
between anti-Ku p80 and joint/bone features (in the
female population of anti-Ku-positive patients, repre-
senting 84% of the overall population). The correlation
is evidently not strong; however, looking at the typical
inflammatory joint disease, such as RA, it is worth men-
tioning the main characteristics of our eight RA patients
showing relatively mild joint affliction. The disease
activity (by ESR and CRP) was (looking longitudinally)
described as high in two patients, medium in two
patients, and low in the rest. The radiographic examina-
tion of the diseased joints was reported as highly
destructive with deformations in one patient and rather
mild with slight narrowing of the joint space and few
erosions in the rest. The immunoserology showed five
seropositive patients (RF-latex and Waaler Rose test
and/or anti-CCP-ELISA) and three seronegative patients
for both. Furthermore, they typically had high titers of
anti-nuclear antibodies. As expected, four patients had
anti-Ro, and two patients had anti-La antibodies.
These results might provide the basis for further stu-
dies of anti-Ku-related pathogenesis, particularly with
respect to joint/bone features. Of interest, Ku p70-knock-
out mice have increased rates of primary mouse ear
fibroblast transformation [24], and embryonic fibroblasts
from Ku 80-knockout mice have a prolonged G2 phase
after H2O2 treatment [5,25]. It would be interesting to
determine the specific roles of the antigens Ku p70/p80
in synovial fibroblasts, especially in DNA-dependent pro-
tein kinase catalytic subunit independent processes.
The compilation of specific clinical signs/symptoms
and the diagnoses-related prevalence of certain organs/
tissues being affected could have introduced a certain
bias in the analyses, because of this targeted approach, as
described in Materials and Methods. Also, patient diag-
noses and clinical signs coming from many different cen-
ters and evaluated by different clinicians could result in
variations of interpretation, and we do not exclude some
possible bias arising from this. However, the representa-
tives from each center were instructed to reevaluate the
clinical charts of all patients included. Concerning the
CIE/LIA anti-Ku-positive group, the lack of ACA (which
had been previously shown [8]) was now confirmed in
our larger anti-Ku-positive SSc group. Just one anti-Ku-
positive case (with antibodies against both subunits) was
ACA positive and diagnosed as having SLE/Sjögren
syndrome.
To compare UCTD with SLE and SSc, and to under-
stand the complexity of clinical features in systemic
autoimmune diseases, we stratified anti-Ku-positive
patients by using PCA. The analysis showed a clear dif-
ferentiation of anti-Ku-positive SLE and SSc patients,
whereas anti-Ku-positive UCTD patients were posi-
tioned in between, with a tendency for greater overlap
of UCTD with SLE than with SSc. In our Caucasian
population of patients, this could imply that the detec-
tion of anti-Ku antibodies might help in stratifying
UCTD.
Conclusions
In conclusion, anti-Ku p70/p80 antibodies are not repre-
sentative markers of a single systemic autoimmune dis-
ease. In our study, we showed a higher prevalence of
antibodies against Ku p70 as compared with anti-Ku
p80. PCA analysis showed that anti-Ku-positive UCTD
patients in our cohort had a greater overlap with anti-
Ku-positive SLE patients than with SSc patients. There-
fore the finding of anti-Ku positivity in UCTD patients
might indicate the progression to SLE.
Anti-Ku p70 was positively and anti-Ku p80 was nega-
tively associated (even after adjustment of the P value)
with joint/bone features, irrespective of diagnosis within
connective tissue diseases, which could be an indication
of the p70 Ku antigen potential speculative protective
role in joint pathophysiology.
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